Form 4: Oncology Institute Chief Clinical Officer Acquires Over 57,000 Shares Through RSU Vesting

Jeffrey Langsam, Chief Clinical Officer of Oncology Institute, Inc., reported the acquisition of 57,380 shares of common stock through the vesting of Restricted Stock Units.

Summary

• Jeffrey Langsam, the Chief Clinical Officer of Oncology Institute, Inc. (TOI), reported a change in beneficial ownership.
• On May 21, 2025, Mr. Langsam acquired 57,380 shares of common stock.
• The acquisition was a result of Restricted Stock Unit (RSU) awards that were fully vested upon grant.
• The reported price for this acquisition was $0, as it represents the vesting of previously granted RSUs, net of withholding tax obligations.
• Following this transaction, Mr. Langsam directly beneficially owns 57,380 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects an increase in insider ownership, which generally aligns management's interests with shareholders. While it's an RSU vesting rather than an open market purchase, it still signifies a commitment to the company's equity.

Positives

• The acquisition of shares by a key executive, even through RSU vesting, increases their direct ownership in the company, aligning their interests more closely with those of shareholders.
• The vesting of RSUs indicates the fulfillment of compensation agreements, which can be a sign of stability in executive compensation plans.

Future Outlook

This Form 4 filing is a report of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a standard insider transaction report and does not provide specific insights into broader industry trends or competitive landscape within the oncology sector. It primarily reflects an individual executive's equity compensation.

Stakeholder Impact

• Shareholders: Increased insider ownership can be viewed positively as it aligns management's financial interests with those of the shareholders, potentially signaling confidence in the company's long-term performance.

Key Dates

Keywords

Oncology Institute, TOI, Jeffrey Langsam, Form 4, Insider Transaction, Beneficial Ownership, Restricted Stock Units, RSU Vesting, Common Stock, Executive Compensation